RO6870810 clinical trials
Also written RO6870810.
- studies test it
- 5
- open now
- 0
- in phase 3
- 0
- first study started
- 2013
How each study uses RO6870810 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorisations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
Studies by the year they started
5 studies that test it; most in 2017 (3)
| Year | Studies |
|---|---|
| 2013 | 1 |
| 2014 | 1 |
| 2017 | 3 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 5
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 5 · Other 0
Studies
Open first, then newest update. How each study uses RO6870810 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 5
- A Study to Evaluate Safety, Pharmacokinetics, and Clinical Activity of Combination of RO6870810 and Venetoclax, With or Without Rituximab, in Participants With Relapsed/Refractory DLBCL and/or High-Grade B-Cell Lymphoma and/or High Grade B-Cell Lymphoma With MYC and/or BCL2 and/or BCL6CompletedPhase 1Hoffmann-La RocheNCT03255096Written as RO6870810
- A Study to Evaluate the Safety, Pharmacokinetics and Clinical Activity of RO6870810 and Atezolizumab (PD-L1 Antibody) in Participants With Advanced Ovarian Cancer or Triple Negative Breast CancerTerminatedPhase 1Hoffmann-La RocheNCT03292172Written as RO6870810
- Study of Bromodomain and Extra-Terminal Protein (BET) Inhibitor RO6870810 as Mono- and Combination Therapy in Advanced Multiple MyelomaCompletedPhase 1Hoffmann-La RocheNCT03068351Written as RO6870810
- A Two Part Study of RO6870810. Dose-Escalation Study in Participants With Advanced Solid Tumors and Expansion Study in Participants With Selected MalignanciesCompletedPhase 1Hoffmann-La RocheNCT01987362Written as RO6870810
- A Study of RO6870810/TEN-010 in Participants With Acute Myeloid Leukemia and Myelodysplastic SyndromeCompletedPhase 1Hoffmann-La RocheNCT02308761Written as RO6870810
Codes
What other systems call RO6870810 · ClinicalTrials.gg INT001830
- NCI Thesaurus C112500BET Inhibitor RO6870810One source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| NCI Thesaurus | C112500 | BET Inhibitor RO6870810 | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.